Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1. 1.

   A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   Recruiting — Phase 3 — AstraZeneca

   https://clinicaltrials.gov/study/NCT06692738

2. 2.

   A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

   Recruiting — Phase 3 — AbbVie

   https://clinicaltrials.gov/study/NCT06461897

3. 3.

   Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

   Recruiting — Phase 3 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT05335876

4. 4.

   Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

   Recruiting — Phase 3 — The University of Queensland

   https://clinicaltrials.gov/study/NCT04939935

5. 5.

   Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

   Recruiting — Phase 3 — UMC Utrecht

   https://clinicaltrials.gov/study/NCT02735707

6. 6.

   Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

   Recruiting — Phase 3 — University College, London

   https://clinicaltrials.gov/study/NCT04685616

7. 7.

   FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

   Recruiting — Phase 1 — University of Birmingham

   https://clinicaltrials.gov/study/NCT04625907

8. 8.

   A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

   Recruiting — Phase 3 — AstraZeneca

   https://clinicaltrials.gov/study/NCT06627647

9. 9.

   A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

   Recruiting — Phase 3 — Cybin IRL Limited

   https://clinicaltrials.gov/study/NCT06793397

10. 10.

    The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

    Recruiting — Na — University of Leicester

    https://clinicaltrials.gov/study/NCT04204915

11. 11.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Recruiting — Phase 3 — Eli Lilly and Company

    https://clinicaltrials.gov/study/NCT07165028

12. 12.

    An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

    Recruiting — Phase 1 — iECURE, Inc.

    https://clinicaltrials.gov/study/NCT06255782

13. 13.

    A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

    Recruiting — Phase 3 — Merus B.V.

    https://clinicaltrials.gov/study/NCT06525220

14. 14.

    Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

    Recruiting — Phase 3 — Iovance Biotherapeutics, Inc.

    https://clinicaltrials.gov/study/NCT05727904

15. 15.

    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

    Recruiting — Phase 3 — BioNTech SE

    https://clinicaltrials.gov/study/NCT06712355

16. 16.

    A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

    Recruiting — Phase 3 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT07225946

17. 17.

    AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT07215585

18. 18.

    ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    Recruiting — Phase 3 — Jazz Pharmaceuticals

    https://clinicaltrials.gov/study/NCT05580562

19. 19.

    Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

    Recruiting — Na — The University of Queensland

    https://clinicaltrials.gov/study/NCT03573089

20. 20.

    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT07218029

21. 21.

    Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06456346

22. 22.

    A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06015737

23. 23.

    A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

    Recruiting — Phase 3 — Merus B.V.

    https://clinicaltrials.gov/study/NCT06496178

24. 24.

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Recruiting — Phase 3 — Amgen

    https://clinicaltrials.gov/study/NCT07037459

25. 25.

    A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

    Recruiting — Phase 3 — Longboard Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06660394

26. 26.

    ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

    Recruiting — University of Michigan

    https://clinicaltrials.gov/study/NCT05388708

27. 27.

    A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    Recruiting — Phase 1 — Bristol-Myers Squibb

    https://clinicaltrials.gov/study/NCT06618287

28. 28.

    A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    Recruiting — Phase 3 — Akero Therapeutics, Inc

    https://clinicaltrials.gov/study/NCT06528314

29. 29.

    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

    Recruiting — Phase 3 — Seagen, a wholly owned subsidiary of Pfizer

    https://clinicaltrials.gov/study/NCT05253651

30. 30.

    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

    Recruiting — Phase 2 — AstraZeneca

    https://clinicaltrials.gov/study/NCT07082738

31. 31.

    A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1

    Recruiting — Phase 1 — Sanofi

    https://clinicaltrials.gov/study/NCT06844214

32. 32.

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    Recruiting — Phase 3 — Akero Therapeutics, Inc

    https://clinicaltrials.gov/study/NCT06215716

33. 33.

    A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

    Recruiting — Phase 3 — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    https://clinicaltrials.gov/study/NCT06615479

34. 34.

    Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

    Recruiting — Phase 3 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT03067181

35. 35.

    The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    Recruiting — Phase 1 — PMV Pharmaceuticals, Inc

    https://clinicaltrials.gov/study/NCT04585750

36. 36.

    A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

    Recruiting — Phase 2 — Amgen

    https://clinicaltrials.gov/study/NCT06570798

37. 37.

    Staphylococcus Aureus Network Adaptive Platform Trial

    Recruiting — Phase 4 — University of Melbourne

    https://clinicaltrials.gov/study/NCT05137119

38. 38.

    Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

    Recruiting — Phase 2 — Biohaven Therapeutics Ltd.

    https://clinicaltrials.gov/study/NCT06309966

39. 39.

    Extension Study for the Port Delivery System With Ranibizumab (Portal)

    Recruiting — Phase 3 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT03683251

40. 40.

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    Recruiting — Phase 3 — Genmab

    https://clinicaltrials.gov/study/NCT06191744

41. 41.

    MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06097728

42. 42.

    Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06120491

43. 43.

    A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Recruiting — Phase 3 — Genmab

    https://clinicaltrials.gov/study/NCT06508658

44. 44.

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Recruiting — Phase 3 — Celgene

    https://clinicaltrials.gov/study/NCT05519085

45. 45.

    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

    Recruiting — Phase 3 — Pfizer

    https://clinicaltrials.gov/study/NCT05611801

46. 46.

    Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

    Recruiting — CHDI Foundation, Inc.

    https://clinicaltrials.gov/study/NCT01574053

47. 47.

    Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    Recruiting — Phase 1 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06395103

48. 48.

    ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

    Recruiting — Phase 3 — Novo Nordisk A/S

    https://clinicaltrials.gov/study/NCT06118281

49. 49.

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Recruiting — Phase 3 — Boehringer Ingelheim

    https://clinicaltrials.gov/study/NCT07064473

50. 50.

    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    Recruiting — Phase 3 — BeOne Medicines

    https://clinicaltrials.gov/study/NCT06943872

51. 51.

    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

    Recruiting — Phase 2 — Bristol-Myers Squibb

    https://clinicaltrials.gov/study/NCT07221357

52. 52.

    Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

    Recruiting — Phase 1 — Dyne Therapeutics

    https://clinicaltrials.gov/study/NCT05481879

53. 53.

    A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

    Recruiting — Phase 1 — Alterome Therapeutics, Inc.

    https://clinicaltrials.gov/study/NCT06533059

54. 54.

    A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

    Recruiting — Phase 2 — Bristol-Myers Squibb

    https://clinicaltrials.gov/study/NCT06855771

55. 55.

    A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06549595

56. 56.

    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

    Recruiting — Phase 3 — Boehringer Ingelheim

    https://clinicaltrials.gov/study/NCT07107945

57. 57.

    A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

    Recruiting — Phase 3 — AbbVie

    https://clinicaltrials.gov/study/NCT06468228

58. 58.

    DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

    Recruiting — Phase 3 — Day One Biopharmaceuticals, Inc.

    https://clinicaltrials.gov/study/NCT05566795

59. 59.

    A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Recruiting — Phase 1 — AstraZeneca

    https://clinicaltrials.gov/study/NCT07123454

60. 60.

    A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

    Recruiting — Phase 3 — Longboard Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06719141

61. 61.

    Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

    Recruiting — Phase 1 — AstraZeneca

    https://clinicaltrials.gov/study/NCT05417594

62. 62.

    A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

    Recruiting — Phase 2 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT06635148

63. 63.

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

    Recruiting — Phase 1 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT04774718

64. 64.

    A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

    Recruiting — Phase 3 — Novartis Pharmaceuticals

    https://clinicaltrials.gov/study/NCT04557462

65. 65.

    A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

    Recruiting — Phase 3 — Inventiva Pharma

    https://clinicaltrials.gov/study/NCT04849728

66. 66.

    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

    Recruiting — Phase 2 — Inhibrx Biosciences, Inc

    https://clinicaltrials.gov/study/NCT06295731

67. 67.

    Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

    Recruiting — AbbVie

    https://clinicaltrials.gov/study/NCT06830759

68. 68.

    A Long-term Extension Study of PCI-32765 (Ibrutinib)

    Recruiting — Phase 3 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT01804686

69. 69.

    An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

    Recruiting — Phase 3 — Servier Affaires Médicales

    https://clinicaltrials.gov/study/NCT05876754

70. 70.

    A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

    Recruiting — Phase 1 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06941272

71. 71.

    Outpatient Treatment With Anti-Coronavirus Immunoglobulin

    Recruiting — Phase 3 — University of Minnesota

    https://clinicaltrials.gov/study/NCT04910269

72. 72.

    Product Surveillance Registry

    Recruiting — Medtronic

    https://clinicaltrials.gov/study/NCT01524276

73. 73.

    Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial

    Recruiting — Phase 3 — Monash University

    https://clinicaltrials.gov/study/NCT05072314

74. 74.

    A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

    Recruiting — Phase 3 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT06819878

75. 75.

    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    Recruiting — Phase 1 — BioNTech SE

    https://clinicaltrials.gov/study/NCT07070232

76. 76.

    A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    Recruiting — Phase 2 — ModernaTX, Inc.

    https://clinicaltrials.gov/study/NCT06735248

77. 77.

    A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    Recruiting — Phase 2 — Day One Biopharmaceuticals, Inc.

    https://clinicaltrials.gov/study/NCT04775485

78. 78.

    A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

    Recruiting — Phase 1 — AstraZeneca

    https://clinicaltrials.gov/study/NCT05938270

79. 79.

    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06312137

80. 80.

    Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

    Recruiting — Sanford Health

    https://clinicaltrials.gov/study/NCT01793168

81. 81.

    EXtubation Related Complications - the EXTUBE Study (EXTUBE)

    Recruiting — University Health Network, Toronto

    https://clinicaltrials.gov/study/NCT06442930

82. 82.

    A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

    Recruiting — Phase 1 — University of Birmingham

    https://clinicaltrials.gov/study/NCT07334301

83. 83.

    Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    Recruiting — Phase 1 — BioNTech SE

    https://clinicaltrials.gov/study/NCT05142189

84. 84.

    Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

    Recruiting — Phase 3 — Sanofi

    https://clinicaltrials.gov/study/NCT06141486

85. 85.

    A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

    Recruiting — Phase 1 — BeOne Medicines

    https://clinicaltrials.gov/study/NCT05006716

86. 86.

    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Recruiting — Phase 3 — Eli Lilly and Company

    https://clinicaltrials.gov/study/NCT06439277

87. 87.

    Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

    Recruiting — Na — Population Health Research Institute

    https://clinicaltrials.gov/study/NCT05701358